The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis.
We investigated the effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in patients with multiple sclerosis. Following a double blind trial designed to compare the effect of oral and intravenous methylprednisolone treatment on promoting recovery from acute relapses...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2000
|
| _version_ | 1797074949078253568 |
|---|---|
| author | Sharrack, B Hughes, R Morris, R Soudain, S Wade-Jones, O Barnes, D Brown, P Britton, T Francis, D Perkin, G Rudge, P Swash, M Katifi, H Farmer, S Frankel, J |
| author_facet | Sharrack, B Hughes, R Morris, R Soudain, S Wade-Jones, O Barnes, D Brown, P Britton, T Francis, D Perkin, G Rudge, P Swash, M Katifi, H Farmer, S Frankel, J |
| author_sort | Sharrack, B |
| collection | OXFORD |
| description | We investigated the effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in patients with multiple sclerosis. Following a double blind trial designed to compare the effect of oral and intravenous methylprednisolone treatment on promoting recovery from acute relapses of multiple sclerosis, 80 patients were followed for two years with six-monthly assessments during which all subsequent relapses were recorded. The annual relapse rate was slightly higher in the oral compared with the intravenous methylprednisolone-treated patients (1.06 vs. 0.78), but the adjusted difference between the two groups was not statistically significant (0.18; 95% CI -0.19 to 0.55, P=0.3). The time to onset and the severity of the first relapse after treatment, the number of relapse free patients at the end of the follow-up period, and the severity of the relapses during the follow-up period were similar in the two groups. This trial did not show a statistically significant difference in relapse rate during the first two years following oral compared with intravenous methylprednisolone treatment. |
| first_indexed | 2024-03-06T23:43:33Z |
| format | Journal article |
| id | oxford-uuid:702239bb-2f96-45e2-a1b7-7b8c6daf4d1d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:43:33Z |
| publishDate | 2000 |
| record_format | dspace |
| spelling | oxford-uuid:702239bb-2f96-45e2-a1b7-7b8c6daf4d1d2022-03-26T19:35:13ZThe effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:702239bb-2f96-45e2-a1b7-7b8c6daf4d1dEnglishSymplectic Elements at Oxford2000Sharrack, BHughes, RMorris, RSoudain, SWade-Jones, OBarnes, DBrown, PBritton, TFrancis, DPerkin, GRudge, PSwash, MKatifi, HFarmer, SFrankel, JWe investigated the effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in patients with multiple sclerosis. Following a double blind trial designed to compare the effect of oral and intravenous methylprednisolone treatment on promoting recovery from acute relapses of multiple sclerosis, 80 patients were followed for two years with six-monthly assessments during which all subsequent relapses were recorded. The annual relapse rate was slightly higher in the oral compared with the intravenous methylprednisolone-treated patients (1.06 vs. 0.78), but the adjusted difference between the two groups was not statistically significant (0.18; 95% CI -0.19 to 0.55, P=0.3). The time to onset and the severity of the first relapse after treatment, the number of relapse free patients at the end of the follow-up period, and the severity of the relapses during the follow-up period were similar in the two groups. This trial did not show a statistically significant difference in relapse rate during the first two years following oral compared with intravenous methylprednisolone treatment. |
| spellingShingle | Sharrack, B Hughes, R Morris, R Soudain, S Wade-Jones, O Barnes, D Brown, P Britton, T Francis, D Perkin, G Rudge, P Swash, M Katifi, H Farmer, S Frankel, J The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis. |
| title | The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis. |
| title_full | The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis. |
| title_fullStr | The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis. |
| title_full_unstemmed | The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis. |
| title_short | The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis. |
| title_sort | effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis |
| work_keys_str_mv | AT sharrackb theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT hughesr theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT morrisr theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT soudains theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT wadejoneso theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT barnesd theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT brownp theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT brittont theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT francisd theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT perking theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT rudgep theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT swashm theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT katifih theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT farmers theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT frankelj theeffectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT sharrackb effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT hughesr effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT morrisr effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT soudains effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT wadejoneso effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT barnesd effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT brownp effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT brittont effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT francisd effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT perking effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT rudgep effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT swashm effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT katifih effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT farmers effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis AT frankelj effectoforalandintravenousmethylprednisolonetreatmentonsubsequentrelapserateinmultiplesclerosis |